GlassScriptPhysician profile
Kelsey L Keoppel
NPI 1003336132
$4,534.35
in general payments reported to CMS, 2019-2025
36 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.77 · 2020: $85.46 · 2021: $473 · 2022: $1,096 · 2023: $1,229 · 2024: $1,160 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,856 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,855.55 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $962.20 | 2022-2025 | |
| Pfizer INC. | $654.75 | 2020-2025 | |
| Lilly USA, LLC | $546.27 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $533.21 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $222.27 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $169.61 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $156.77 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.37 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $132.41 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Dexcom, INC. | $104.38 | 2022-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.11 | 2022-2025 | Xifaxan |
| Amgen INC. | $87.33 | 2021-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $79.44 | 2021-2022 | |
| Exact Sciences Corporation | $58.25 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $53.54 | 2023-2024 | Freestyle Libre 3 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.78 | 2021-2025 | Spravato |
| Mylan Specialty L.P. | $39.87 | 2022-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $37.25 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $35.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.76 | 2023 | Trintellix |
| Genentech USA, INC. | $32.24 | 2020-2022 | |
| Amarin Pharma, INC. | $31.92 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $31.83 | 2020-2021 | |
| Axsome Therapeutics, INC. | $27.83 | 2025 | Symbravo |
| Eisai INC. | $24.12 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $23.64 | 2021 | |
| Harmony Biosciences LLC | $22.92 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.12 | 2022 | |
| Astellas Pharma US INC | $21.25 | 2024 | Veozah |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.23 | 2024 | |
| Dynavax Technologies Corporation | $19.27 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.98 | 2023 | Quviviq |
| Lundbeck LLC | $14.11 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.57 | 2023 | |
| Organon LLC | $12.22 | 2022 | |
| Corium, LLC | $3.45 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Keoppel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.